Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

Share Price is delayed by 15 minutes
Get Live Data
98.90    -1.20 (-1.20%)
Bid:
99.22
Ask:
99.28
Spread: 0.06 (0.06%)
Market Cap: £57.64b
LLOY Live PriceLast checked at - London Stock Exchange

Intraday Lloyds Share Chart

Publication of Suppl.Prospcts

2 May 2025 11:15

RNS Number : 2647H
Lloyds Bank PLC
02 May 2025
 

 

2 May 2025

Publication of Supplementary Prospectus

The following Supplementary Prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Supplementary Prospectus dated 2 May 2025 (the "Supplementary Prospectus") relating to the £35,000,000,000 Euro Medium Term Note Programme of Lloyds Bank plc.

The Supplementary Prospectus should be read and construed in conjunction with the prospectus dated 28 March 2025 relating to the above programme (the "Prospectus").

To view the Supplementary Prospectus, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/2647H_1-2025-5-2.pdf

The Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Investor Relations:

Douglas Radcliffe

Group Investor Relations Director

Tel: +44 (0) 20 7356 1571

Email: douglas.radcliffe@lloydsbanking.com

 

Group Corporate Treasury

Kristofer Middleton

Head of Term Issuance and Capital Structuring

Tel: +44 (0) 207 356 1122

Email: Kristofer.Middleton@lloydsbanking.com

 

Group Corporate Affairs:

Matt Smith

Head of Media Relations

Tel: +44 (0) 7788 352 487

Email: matt.smith@lloydsbanking.com

Lloyds Bank plc

25 Gresham Street,

London EC2V 7HN

United Kingdom

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in this announcement and the Supplementary Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Supplementary Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Supplementary Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Supplementary Prospectus.

In particular, this announcement and the Supplementary Prospectus do not constitute an offer or invitation to subscribe for, or purchase securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Supplementary Prospectus are not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPFLFLIELIFIIE
Date   Source Headline
2nd Mar 20266:04 pmRNSTransaction in Own Shares
2nd Mar 20264:25 pmRNSIssue of Equity
27th Feb 20266:00 pmRNSTransaction in Own Shares
27th Feb 20264:18 pmRNSTotal Voting Rights
27th Feb 20262:49 pmRNSPublication of a Supplementary Prospectus
27th Feb 20261:32 pmRNSPublication of a Supplementary Prospectus
26th Feb 20265:57 pmRNSTransaction in Own Shares
26th Feb 20262:58 pmRNS2025 Form 20F Filed
26th Feb 202611:57 amRNS2025 Annual Report and Accounts
26th Feb 202611:57 amRNS2025 Annual Report and Accounts
26th Feb 202611:57 amRNS2025 Annual Report and Accounts
25th Feb 20266:19 pmRNSTransaction in Own Shares
25th Feb 20269:00 amRNS2025 Annual Report and Accounts
24th Feb 20266:03 pmRNSTransaction in Own Shares
23rd Feb 20265:50 pmRNSTransaction in Own Shares
20th Feb 20266:05 pmRNSTransaction in Own Shares
19th Feb 20266:08 pmRNSTransaction in Own Shares
18th Feb 20266:09 pmRNSTransaction in Own Shares
17th Feb 20265:56 pmRNSTransaction in Own Shares
16th Feb 20265:59 pmRNSTransaction in Own Shares
16th Feb 20261:02 pmRNSPublication of a Supplementary Prospectus
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20261:52 pmRNS2025 Form 20F Filed
13th Feb 202610:32 amRNS2025 Annual Report and Accounts
12th Feb 20265:51 pmRNSTransaction in Own Shares
11th Feb 20265:56 pmRNSTransaction in Own Shares
11th Feb 20262:00 pmRNSDirector/PDMR Shareholding
10th Feb 20265:54 pmRNSTransaction in Own Shares
10th Feb 20262:14 pmRNSPublication of Final Terms
9th Feb 20266:16 pmRNSTransaction in Own Shares
6th Feb 20266:04 pmRNSTransaction in Own Shares
5th Feb 20266:01 pmRNSTransaction in Own Shares
5th Feb 20262:00 pmRNSDirector/PDMR Shareholding
4th Feb 20266:07 pmRNSTransaction in Own Shares
3rd Feb 20266:16 pmRNSTransaction in Own Shares
2nd Feb 20266:25 pmRNSTransaction in Own Shares
30th Jan 20266:20 pmRNSTransaction in Own Shares
30th Jan 20263:18 pmRNSTotal Voting Rights
30th Jan 202611:30 amRNSPublication of a Supplementary Prospectus
30th Jan 20267:02 amRNSCommencement of Share Buyback Programme
29th Jan 202612:00 pmRNSBoard Committee Change
29th Jan 20267:00 amRNS2025 results
22nd Jan 202610:42 amRNSNotification of Redemption
19th Jan 20267:00 amRNSUpdate in respect of block listing of shares
13th Jan 20264:22 pmRNSDirector/PDMR Shareholding
2nd Jan 202610:00 amRNSBlock listing Interim Review
31st Dec 202511:00 amRNSTotal Voting Rights
31st Dec 202511:00 amRNSTotal Voting Rights
22nd Dec 20253:06 pmRNSDirector/PDMR Shareholding
22nd Dec 20253:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.